Drug intelligence / Profile preview

YZJ-2440

Development stage: Unknown
Lead developer: Yangtze River Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

YZJ-2440 is an investigational small molecule inhibitor targeting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). It is being developed primarily for the treatment of advanced solid tumors. The drug acts by inhibiting CDK4 and CDK6, which are key regulators of cell cycle progression from G1 to S phase, thereby potentially halting tumor cell proliferation. The compound was initially developed by Jiangsu Yangtze River Pharmaceutical Group. Clinical trials are ongoing to determine its safety, tolerability, pharmacokinetics, and recommended dosing in patients with advanced solid tumors[1][2][3].

Other names: YZJ-2440 maleateYZJ2440 maleateYZJ 2440 maleate

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on YZJ-2440.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZJ-2440.

Explore the full profile